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Abstract
Aim
The aim of the present study was to assess the estimated “per patient” total cost for a single
Oncologic Italian Cancer Center pa!rticipating in a multicenter clinical trial with new antican-
cer biological agents using the activity-based costing (ABC) methodology.
Methodology
Nine randomized phase 3 clinical trials employing biological agents at the National Cancer
Institute of Napoli, Italy, were analyzed to indentify “per patient” costs of each trial, according
to the ABC methodology. The average consumption of resources for a patient completing
the entire planned treatment was estimated for each trial. Through interviews of the person-
nel (doctors, nurses and technicians) and by analyses of the clinical trials protocols, the
main activities of the 9 clinical trials were identified and, for each trial, the complete health
care pathway of the patients and the treatment programmes were minutely reconstructed.
Drug costs were not included because provided by Sponsors.
Principal findings
The average costs of the pre-study, treatment, monitoring, follow-up, audit, and administra-
tive activities accounted for 2.357, 4.783, 700, 372, 1.263, and 9 Euro, respectively. The
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average total cost estimated for all “per patient” activities, including overhead costs, was
11.379 Euro. Staff costs accounted for€ 5.988, while costs of diagnostic test accounted for
3.494 Euro. Clinical trials with immunotherapeutic drugs accounted for higher costs (+601
Euro as oncological staff costs, +1.318 Euro as intermediate services cost and +384 Euro
as overheads).
Conclusions
The average total cost estimated for all “per patient” activities of a clinical trial with new anti-
cancer biological agents was 11.379 Euro using the ABC methodology.
Introduction
Clinical research plays a critical role for drugs development. However, cost of clinical trials for
a participating clinical centre is currently unknown and difficult to determine [1]. Revenues
are quite easy to measure, as they are related to the activities specified in the clinical trial proto-
col, but the same cannot be said for costs.
According to the traditional managerial accounting systems based on cost centers, the costs
typically related to the activities of clinical trials are mostly indirect (staff costs, diagnostic test
costs, medical instruments maintenance and depreciation costs, etc), as it is not possible to
assess the amount of any specific resource used for each trial through objective measure.
Therefore, all production costs are charged directly to the center where the consumption of
the resources takes place and only indirectly to the patients receiving the treatment.
In this context, the activity-based costing (ABC) methodology can be used to overcome the
shortfalls of the traditional cost accounting systems, especially when indirect costs, not directly
traceable to the products-services, represent an important proportion of the total cost [2]. ABC
traces the resources to activities to facilitate costing of products and services. It assumes that
activities consume resources and products consume activities. Therefore, indirect production
costs are first assigned to the activities (through appropriate resources driver), determining the
costs of the identified activities. Then, the activities costs are allocated to products or services,
according to the activities consumed by each of them, using activity measures and activity
rates [3]. Accordingly, ABC allows to determine the standard full cost per service unit provided
by the hospital (for instance, the unit patient cost), as a tool for administrative cost informa-
tion, strategic decision-making, quality and efficiency improvement [3].
The aim of the present study was to assess the estimated “per patient” total cost for a single
Oncologic Italian Cancer Center participating in a multicenter clinical trial with new antican-
cer biological agents using the ABC methodology, with the purpose to develop a model capable
of providing accurate and relevant economic information for a “profit” clinical trial.
Methods
ABC in health care organization follows the same typical steps of ABC systems implemented
in a manufacturing company [4–6]. It includes: setting the key variables (cost objects, main
activities and resources used); defining a process-based map representing the flow of the activi-
ties, resources and their interrelationships; allocating resources cost to activity pool; attribu-
tions of secondary activities cost to primary activities, assessing activity consume by each cost
objects; computing activity rate; sharing activities cost to products that caused that activity [7].
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The cost objects have been identified in the patients participating into profit randomized
clinical trials with either immunotherapeutic or target based agents. Therefore, we have ana-
lyzed nine randomized phase 3 clinical trials with new anticancer biological agents carried out
at the Thoracic, Melanoma, and Uro-Gynecological Medical Oncology of the National Cancer
Institute of Napoli, Italy in order to indentify “per patient” costs. For each trial we considered
an “ideal patient” representing the consumption of resources for completing the entire
planned treatment. We used semi-structured interviews with the principal investigators and
key personnel (doctors, nurses and technicians) to identify the primary activities required by
the patients of 9 clinical trials, reported in S1 Table and S1 Text. All employees provided their
oral informed consent to have their interviews used in the study.
Through key personnel interviews and by analyses of the clinical trials protocols, it was
minutely reconstructed the whole patient hospital pathway and the treatment schedule, the
time required to perform all the planned activities, the name and the role of the employees
who performed them (e.g., doctors, nurses, pharmacists, laboratory technicians, x-ray techni-
cians, study coordinators, etc.) for all unit involved in the studies (Fig 1).
Fig 1. Patient clinical pathway of a clinical study.
https://doi.org/10.1371/journal.pone.0210330.g001
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About resources’ cost used, we have considered only two main cost categories, those related
to staff involved and diagnostic tests performed in the clinical study, because we didn’t have
already defined costs provided by cost center accounting system. The staff’s cost was estimated
multiplicand the company hourly labour cost of each employee for the time required to per-
form a certain activity, both express in minutes, while the cost of the diagnostic tests and other
procedures was estimated by using public local health reimbursement [8]. All other costs, not
directly related to a specific activity, were included in an overhead cost category estimated at
20% of the cost of all activities performed, comprehensive of costs connected with infrastruc-
tures and the general operation of the organisation, including hiring or depreciation of build-
ings and plants, water/gas/electricity, maintenances, insurances, supplies and petty office
equipments, communication and connection costs, postage, and costs connected with hori-
zontal services such as administrative and financial management, human resources, training,
legal advice, documentation, etc. Finally, drug costs were not included because provided by
the sponsor.
We built an Expense-Activity-Link Matrix (EAL-matrix) for each clinical trial examined as
illustrated in S2 Table. The EAL-matrix reflects the first stage of cost assignment and repre-
sents a first map of interrelations between activities performed and resources consumed. In
the first column we find the main activities performed grouped into activity pools, in the mid-
dle columns the Units involved in clinical trials and the type of resource consumed by activi-
ties, differentiated in staffs and diagnostics tests costs. The last column on the right shows the
cost of every activity pool obtained by adding the corresponding value of the resources con-
sumed. So we used the time spent on each activity as resource driver to allocate the staff costs
and the number of tests by type required to drive the cost of the diagnostic tests, while their
monetary valuation was done using hourly labour cost and through the system of healthcare
reimbursement, respectively. Since we hypothesized the enrollment of a single patient type, the
last column of EAL-Matrix represents also the activities demand value made by patient. There-
fore, our patient type has alone requested and consumed all the activities identified, plus an
amount of consumption of intermediate and facility services, that we estimated equal to 20%
of all activities’ cost demanded.
Since the clinical trials were structured differently, in order to facilitate also data representa-
tion, a bridging table was developed by grouping all the primary activities performed in six
main categories, as follows: a) pre-study activities, including “Pre-Study Site Visit, Enrollment
and Screening Phases”; b) treatment, including “Cycles, Restaging and Exit Cancer Visit”; c)
trial monitoring; d) follow-up; e) audit (generally only one for each study); f) administrative
activities. Therefore, we summarized all data related to the 9 clinical trials in a new EAL-matrix
(S3 Table). Like the EAL-matrix, also the new EAL-Matrix shows the main activities per-
formed (rows), and the organizational units involved in patient’s care process to perform diag-
nostic tests required by clinical trial protocol (column).
Results
The characteristics of the 9 clinical trials carried out with anticancer biological agents from 2014
to 2016 at the National Cancer Institute of Napoli Italy are reported in Table 1. They were all
randomized clinical trials with immunotherapeutic or target based agents for melanoma, lung
and ovarian cancers. The results for each clinical trial are summarized in S4–S6 Tables, while
details in term of resources consumed, differentiate in staff and test costs, are specified in S7–S9
Tables. Using EAL-Matrix setting, in S10–12 Tables, we have provided a detail of staff involved
in each study and replaced the costs with the time spent in minutes. We then grouped the same
data for staff roles in order to facilitate the overall calculation of the time spent by each operator
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on the activities identified. S13 Table reports, instead, the minimum and maximum hourly rates
differentiated for staff role, as well as the minimum and maximum hourly rates for staff role for
each clinical study. Some differences in hourly cost for the same staff role are related to general
employment contract provisions (i.e., project contract rather than permanent contract work).
Finally, S14 Table shows the diagnostic tests’ type and cost for each clinical study (in original
language) and S15 Table is an example of collected data of a clinical trial used to estimate the”-
per patient” total cost. In Table 2 are reported, instead, the estimated cost of the primary activi-
ties, the overall cost of the activities performed by the single units involved in the study and,
finally, the estimated “per patient” total cost of all nine studies.
The average costs of pre-study, treatment, monitoring, follow-up, audit, and administrative
activities accounted for 2.357, 4.783, 700, 372, 1.263, and 9 Euro, respectively. The average
total cost estimated for all activities accounted for 9.484 Euro. Overall, the average estimated
“per patient” cost, including the overhead costs, accounted for 11.379 Euro.
The activities related to patients’ treatment take up, still in average, about the 50,44% of the
resources’ cost used (excluding the overhead costs share). Pre-study, trial monitoring and
audit activities roughly represented 46%, while follow-up and administrative activities approx-
imately 3,92% and 0,09% respectively (Fig 2).
Fig 3 shows the estimated cost of resources in its two main components (staff costs and
diagnostic test costs), grouped on the Units involved in patients care. In average, staff costs
accounted for 5.988 Euro, while costs of diagnostic test accounted for 3.494 Euro. Overall, staff
Table 1. Characteristics of the trials.
Type of cancer Drug class Investigational drug Setting
Ovarian PARP inhibitor Rucaparib Maintenance therapy
Urothelial Anti PD-1 inhibitor Pembrolizumab Second line therapy
Ovarian PARP inhibitor Olaparib Maintenance therapy
Lung Anti PD-1 inhibitor Nivolumab First line therapy
Lung Anti EGFR tyrosine kinase inhibitor Dacomitinib 3–4 line therapy
Lung Anti HER 3 monoclonal antibody Patritumab 2–3 line therapy
Melanoma Anti PD-1 inhibitor Nivolumab 2 line therapy
Melanoma Anti PD-1 inhibitor Pembrolizumab 2 line therapy
Melanoma BRAF inhibitor Vemurafenib Pretreated or not
https://doi.org/10.1371/journal.pone.0210330.t001
Table 2. EAL matrix (average costs “per patients” of all studies).
ACTIVITY
POOL
MEDICAL
ONCOLOGIES
RADIODIOLOGY NUCLEAR
MEDICINE
PHARMACY CLINICAL
LABORATORY
PATHOLOGY CARDIOLOGY MOLECULAR
BIOLOGY
ACTIVITY
COST POOL
PRE-STUDY
ACTIVITIES
643,37 837,08 29,90 89,51 490,82 38,57 211,80 15,71 2.356,75
TREATMENT 552,00 1.934,02 106,80 516,21 1.596,32 0,00 59,73 17,72 4.782,80
TRIAL
MONITORING
699,72 0,00 0,00 0,00 0,00 0,00 0,00 0,00 699,72
FOLLOW-UP 115,07 0,00 0,00 0,00 256,91 0,00 0,00 0,00 371,98
AUDIT 804,71 130,00 8,40 63,28 25,30 0,00 225,91 5,32 1.262,92
ADMINISTRATIVE
ACTIVITY
8,68 0,00 0,00 0,00 0,00 0,00 0,00 0,00 8,68
ESTIMATED
TOTAL COST
2.823,55 2.901,09 145,09 669,00 2.369,36 38,57 497,44 38,75 9.482,85
OVERHEAD COST (20%) 1.896,57
ESTIMATED TRIAL TOTAL COST 11.379,42
https://doi.org/10.1371/journal.pone.0210330.t002
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Fig 2. Incidence rates of activity cost pool.
https://doi.org/10.1371/journal.pone.0210330.g002
Fig 3. Cost composition separate for organizational unit involved (average values).
https://doi.org/10.1371/journal.pone.0210330.g003
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costs account for about 63% of the estimated activity cost pool, without overhead costs. The
total costs of each clinical trial, grouped in three main categories, including staff, diagnostic
test and overhead costs are reported in Fig 4. Considering also overhead costs share, staff and
diagnostic costs both decrease from 63% to 52% and from 37% to 30% respectively.
The average cost of the nine studies grouped according to the typology of the experimental
drug (5 studies with target based agents and 4 studies with immunotherapeutic drugs) are
reported in Fig 5. The collected data indicate that the clinical trials with immunotherapeutic
drugs accounted for higher costs (+601 Euro as oncologic staff costs, +1.318 Euro as interme-
diate services costs and +384 Euro as overhead costs). In average, a trial with immunotherapy
drugs accounts for 12.659 Euro per patient, namely 2.302 Euro more than a clinical trial with
target based agents.
Discussion
This study tried to define the estimated “per patient” total cost for a single Oncologic Italian
Cancer Center participating in a multicenter clinical trial with new anticancer biologic agents
by using the concepts underlying the ABC methodology, with the purpose of providing an
accurate and relevant economic information for conduction of clinical trials. The results of the
study showed that estimated “per patient” cost accounted in average for 11.379 Euro. This cost
was obtained by adding the costs of all the activities (pre-study, treatment, monitoring, follow-
up, audit, and administrative activities) to the overhead costs share. Pre-study activities
(20,71% vs 24,85 without overhead costs share), trial monitoring (6,15% vs 7,38% without
overhead costs share) and audit (11,10% vs 13,32% without overhead costs share) accounted
for roughly 38% (about 46% if we don’t consider overhead costs share) of the estimated
patient’s care cost, while treatment accounted for 42% (this value grows to approximately 50%
without overhead costs). It is important to consider that not all costs related to the activities
vary with the number of patients. Pre study site visit, trial monitoring and audit are fixed costs
and they must be computed not more than once for the total patient cost calculation: therefore,
the higher the number of enrolled patients the lower will be their unit cost.
Fig 4. Cost composition separate for clinical trial.
https://doi.org/10.1371/journal.pone.0210330.g004
Costs of CT with anticancer biologic agents in an Oncologic Italian Cancer Center using the ABC methodology
PLOS ONE | https://doi.org/10.1371/journal.pone.0210330 January 8, 2019 7 / 12
Radiodiagnostic service had an estimated cost higher than medical oncology units (2.901 vs
2.824 Euro), but most of the cost was due to tariff value of diagnostic tests performed, equal to
75% of the total cost (as shown in Fig 3), while only the remaining 25% was related to test
interpretation.
Generally, the cost of test interpretation is already included in the reimbursement tariff
value, but the interviews with key personnel revealed that the diagnostic interpretation of the
tests performed in clinical trials is more complex compared to those performed in ordinary
diagnostic medical imaging practice and it may require a longer time, due to particular condi-
tion such as pseudo-progression that should be carefully evaluated. The greater complexity of
clinical trials with immunotherapeutic agents could explain their higher costs compared to
clinical trials with target based agents (+22%), mostly related to a greater number of cycles and
restaging activities.
In addition to the cost data, the model provides additional information, including: the
duration and the number of times that a particular activity has been performed, the number of
tests and procedures required by the studies, the possibility to verify the composition of labor
cost, i.e., for professional profile and/or specific contractual type, the incidence of personnel
cost and the weight of exams on the overall cost, the organizational unit that has supported the
larger effort.
A few data on the costs of clinical trials are available in literature. Emanuel EJ and collabo-
rators [9] indicated that, excluding the overhead expenses, a clinical trial on average costs
slightly more than 6,094 Dollars (ranging from 2,098 to 19,285) “per enrolled patient” for an
industry-sponsored trial, including 1,999 Dollars devoted to nonclinical costs. M.D. Anderson
Cancer Center showed that the average cost for treating patients enrolled in clinical trials was
13,802 Dollars for ovarian cancer, 15,650 Dollars per patient for lung cancer, 16,775 Dollars
for prostate cancer [10]. In contrast, a study of four companies found that the “per patient”
costs for an industry-sponsored study ranged from 60,000 to 85,000 Dollars for Phase III stud-
ies [11]. In the study of Sertkaya A and collaborators, aggregate data from three proprietary
Fig 5. Cost composition separate for the type of the experimental drug (average value).
https://doi.org/10.1371/journal.pone.0210330.g005
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databases on clinical trial costs provided by Medidata Solutions were used [12]. The three data-
bases showed that the top three cost drivers of clinical trial expenditures were clinical proce-
dure costs (15%–22% of total), administrative staff costs (11%–29% of total), and site
monitoring costs (9%–14% of total), excluding estimated site overhead costs and costs for
sponsors to monitor the study. A comprehensive cost item list was exemplified by Speich B
et al. through a retrospective assessment of resource used and costs in two investigator-initi-
ated randomized trials conducted in Switzerland and Tanzania [13]. The resource used was
empirically assessed in a standardized manner through semi-structured interviews and a sys-
tematically developed cost item list. The assessed cost data indicated that the patient enroll-
ment, treatment, and follow-up phase represented in each case the most expensive part (84.2%
and 46.3%, respectively), as in our study. However, both trials were not conducted with onco-
logical drugs and the authors included in the analysis further items such as trial conception,
planning and preparation that may not be generalizable to trials funded by pharmaceutical
companies and that were not evaluated in our study.
The present study has several potential limitations. First of all, “per patient” cost was esti-
mated based on protocol procedures rather than measured. Secondly, we obtained informa-
tion regarding the time to perform activity through key-staffs interviews method. Thus, the
time could be overestimated or underestimated. Moreover, considering that not all costs are
variable, it is to be expected that as the number of enrolled patients increases, their unit cost
decrease. Finally, actual costs of the drugs were not calculated in our study, because they were
entirely supplied by the Sponsor.
In conclusion, the evaluation of the cost of a clinical trial is a complex activity. In the pres-
ent study we assessed the estimated “per patient” total cost for an Oncologic Italian Cancer
Center participating in a multicenter clinical trial with new anticancer biological agents
through the ABC methodology that is a model for separating clinical trial costs from those
related to other clinical activities, looking for an impartial system to ensure a fair remuneration
for services required to cost centers (such as those provided by radiology, clinical laboratory,
cardiology or pathology). Therefore, this study could allow a better understanding of the
nature of the costs produced by clinical trials, providing data and information previously
unknown and not available by using traditional cost-center-based accounting systems, that
help to improve decision making processes. However, this model can be used to better under-
stand the expenses produced by clinical trials also in non Oncologic settings, to estimate a reli-
able budget before starting a trial and to support the Hospital in solving issues related to the
daily clinical activities and to the costs of the provided services.
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